Zebrafish (Danio rerio): A potential model to assess developmental toxicity of ketamine

Ketamine is a non-competitive antagonist of NMDA glutamate receptor. It is used as an anesthetic, analgesic, sedative, and anti-depressive agent in clinical practice and also an illegal recreational drug. The increasing use has contributed to the measurable levels of ketamine in both wastewaters and hospital effluents, thereby classified as an emergent contaminant. Lately, the potential toxicity of ketamine has raised serious concerns about its iatrogenic or illicit use during pregnancy, neonatal and childhood stages. However, to assess its long-term toxicity potentially by the use of early life stages in human and rodents is limited. In this regard, the zebrafish has been considered as excellent model organism for biosafety assessments of ketamine due to it boasts an in vivo model with the advantages of an in vitro assay. In this review, we summarize the current understanding of the reported toxicity studies with ketamine in early life stage of zebrafish. The adverse effects of ketamine are known to cause overall developmental and multi-organ toxicity, including cardio-, neuro-, and skeletal toxicity. Furthermore, multiple mechanisms are found to be responsible for perpetrating toxicity of ketamine. The current findings confluence to emphasize the zebrafish embryo as an appealing model system for developmental toxicity testing in higher vertebrates.

Automated summary

Ketamine, a drug commonly used as an anesthetic and also known as an illegal recreational drug, has been detected in wastewater and hospital effluents. The long-term toxicity of ketamine during early life stages in humans and rodents is still poorly understood. Zebrafish has emerged as a valuable model organism for assessing the developmental toxicity of ketamine, highlighting its potential as a biosafety model for higher vertebrates.